Impact
We are dedicated to improving patient lives through discovery science.
Our research is already making a positive impact for patients and their families. From developing innovative diagnostic tests to advancing imaging methods, we are translating our findings through clinical trials, partnerships, and spin-out companies.
-
3 Personalised medicine programmes
-
14 Spin-out companies created
-
107 Patents filed
-
200 PhD students trained
-
750 Our papers have been cited 750,000 times
Impact
We’re working with clinicians and industry partners to make a meaningful difference for cancer patients, moving towards our vision of a world free from the fear of cancer.
-
Improving the treatment experience of patients living with one of the most challenging cancers
A discovery made in our Miller Lab is allowing researchers and clinicians to trial a drug to improve patients’ quality of life and the effectiveness of pancreatic cancer treatments.
Find out more -
Transforming cancer treatment with OlaparibÂ
Olaparib has significantly impacted patient outcomes, with over 140,000 patients treated, reducing disease progression and death by up to 66%.
Find out more -
Non-invasive tests to improve cancer detectionÂ
Cambridge researchers have developed new methods for detecting and monitoring cancer through simple blood tests.
Find out more -
Next generation DNA sequencing
The development of Next Generation Sequencing technology has reduced the time and cost of sequencing DNA.
Find out more -
Personalising treatment for ovarian cancer patients: BriTROC-2
BriTROC-2 is a nationwide project  developing personalised treatments for women diagnosed with High Grade Serous Ovarian Cancer.Â
Find out more -
AI powered early detection of Barrett’s oesophagusÂ
Artificial intelligence (AI) could help free up pathologist time and allow them to focus on diagnosing the trickiest cases of Barrett’s oesophagus.Â
Find out more